Screening for activated protein C resistance before oral contraceptive treatment: A pilot study

Contraception

Volumn 59, Issue 5, 1999, Pages 293-299

  Palareti, G ^a   Legnani, C ^a   Frascaro, M ^a   Flamigni, C ^a   Gammi, L ^b   Gola, G ^b   Fuschini, G ^b   Coccheri, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Azienda USL di Bologna   (Italy)

Author keywords

Activated protein C resistance; Factor V Leiden; Oral contraceptives; Pill; Screening; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; ARTICLE; CONTRACEPTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; FEMALE; HUMAN; LIFE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; SCREENING; THROMBOPHILIA; VEIN THROMBOSIS;

CONGENITAL ABNORMALITIES--WOMEN; CONTRACEPTION; CONTRACEPTIVE METHODS; COST EFFECTIVENESS; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; EUROPE; EVALUATION; EVALUATION INDEXES; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; ITALY; MEDITERRANEAN COUNTRIES; NEONATAL DISEASES AND ABNORMALITIES; ORAL CONTRACEPTIVES; QUANTITATIVE EVALUATION; RESEARCH REPORT; SCREENING--WOMEN; SOUTHERN EUROPE; THROMBOEMBOLISM; THROMBOSIS--WOMEN; VASCULAR DISEASES; WOMEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTITHROMBIN III; CONTRACEPTIVES, ORAL; COST-BENEFIT ANALYSIS; FACTOR V; FEASIBILITY STUDIES; FEMALE; HUMANS; ITALY; MASS SCREENING; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C; PROTEIN S; PUERPERAL DISORDERS;

EID: 0032819298     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00033-5     Document Type: Article

References (31)

1. Helmerhorst F.M., Bloemenkamp K.W.M., Rosendaal F.R., Vandenbroucke J.P. Oral contraceptives and thrombotic disease risk of venous thromboembolism . Thromb Haemost. 78:1997;327-333.
2. Koster T., Small R.A., Rosendaal F.R., Helmerhorst F.M. Oral contraceptives and venous thromboembolism a quantitative discussion of the uncertainties . J Intern Med. 238:1995;31-37.
3. Douketis J.D., Ginsberg J.S., Holbrook A., Crowther M., Duku E.K., Burrows R.F. A re-evaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med. 157:1997;1522-1530.
4. Farley T.M.M., Meirik O., Chang C.L., Marmot M.G., Poulter N.R. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
5. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 346:1995;1589-1593.
6. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Buller H.R., Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet. 346:1995;1593-1596.
7. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., Macrae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders an international case-control study . Br Med J. 312:1996;83-88.
8. Farmer R.D.T., Lawrenson R.A. Third-generation oral contraceptives and venous thrombosis - reply. Lancet. 349:1997;732-733.
9. Lane D.A., Mannucci P.M., Bauer K.A., et al. Inherited thrombophilia. 1. Thromb Haemost. 76:1996;651-662.
10. Pabinger I., Schneider B., Scharrer I., et al. Thrombotic risk of women with hereditary antithrombin III-, protein c- and protein s-deficiency taking oral contraceptive medication. Thromb Haemost. 71:1994;548-552.
11. Hellgren M., Svensson P.J., Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-213.
12. Vandenbroucke J.P., Vandermeer F.J.M., Helmerhorst F.M., Rosendaal F.R. Factor V Leiden should we screen oral contraceptive users and pregnant women? Br Med J. 313:1996;1127-1130.
13. De Ronde H., Bertina R.M. Laboratory diagnosis of APC-resistance a critical evaluation of the test and the development of diagnostic criteria . Thromb Haemost. 72:1994;880-886.
14. Girolami A., Simioni P., Girolami B., Zanardi S. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors - a study of six patients. Blood Coagul Fibrinolysis. 2:1991;673-678.
15. Girolami A., Zanon E., Zanardi S., Saracino M.A., Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 7:1996;497-501.
16. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
17. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457.
18. De Stefano V., Finazzi G., Mannucci P.M. Inherited thrombophilia pathogenesis, clinical syndromes, and management . Blood. 87:1996;3531-3544.
19. Rodeghiero F., Tosetto A. The VITA project population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen relationship with physiological variables and establishment of reference ranges . Thromb Haemost. 76:1996;226-233.
20. Mannucci P., Duca F., Peyvandi F., et al. Frequency of factor V Arg506 Gln in Italians. Thromb Haemost. 75:1996;694.
21. Tosetto A., Missiaglia E., Gatto E., Rodeghiero F. The VITA project phenotypic resistance to activated protein C and FV Leiden mutation in the general population . Thromb Haemost. 78:1997;859-863.
22. Legnani C., Palareti G., Biagi R., et al. Activated protein C resistance a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation . Br J Haematol. 93:1996;694-699.
23. Tripodi A., Negri B., Bertina R.M., Mannucci P.M. Screening for the FV:α(506) mutation - evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost. 77:1997;436-439.
24. Bertina R.M. Introduction hypercoagulable states . Semin Hematol. 34:1997;167-170.
25. Schambeck C.M., Schwender S., Haubitz I., Geisen U.E., Grossmann R.E., Keller F. Selective screening for the factor V Leiden mutation is it advisable prior to the prescription of oral contraceptives? Thromb Haemost. 78:1997;1480-1483.
26. Girard M. Thromoboembolism and the combined oral contraceptive. Lancet. 346:1995;317.
27. Altes A., Souto J.C., Mateo J., Borrell M., Fontcuberta J. Activated protein C resistance assay when applied in the general population. Am J Obstet Gynecol. 176:1997;358-359.
28. Martinelli I., Rosendaal F.R., Vandenbroucke J.P., Mannucci P.M. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost. 76:1996;477-478.
29. De Stefano V., Leone G., Mastrangelo S., et al. Clinical manifestations and management of inherited thrombophilia retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S . Thromb Haemost. 72:1994;352-358.
30. Svensson P.J., Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 330:1994;517-522.
31. Mcpherson K. Third generation oral contraception and venous thromboembolism - the published evidence confirms the committee on safety of medicine's concerns. Br Med J. 312:1996;68-69.